A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients, are left untreated. Conventional gene therapy is an attractive potential treatment approach for only a limited number of monogenic diseases due to the challenges caused by the complex biology of neurological diseases and by inherent variable transgene uptake and expression. We are a clinical-stage biotechnology company committed to overcoming these limitations and turning today’s complex devastating neurological diseases into treatable conditions. By harnessing our proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning), we are building a robust and differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet need not otherwise addressable by conventional gene therapy.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 0 | - | - | 1.0B |
| Net Income | -85M | -75M | -36M | -58M | -61M | -69M |
| EPS | $-4.10 | $-4.28 | $-2.43 | $-20.80 | $-22.00 | $-51.40 |
| Free Cash Flow | -78M | -71M | -52M | -47M | -51M | -16M |
| ROIC | -38631.0% | -24.2% | -19.5% | -60.9% | -42.5% | -48.3% |
| Gross Margin | - | - | - | - | - | 0.0% |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | - |
| Dividends/Share | $0.00 | - | - | - | - | $0.00 |
| Operating Income | -97M | -83M | -56M | -59M | -61M | -71M |
| Operating Margin | 0.0% | - | - | - | - | -7.1% |
| ROE | -32.1% | -30.3% | -19.5% | -48.5% | -42.5% | - |
| Shares Outstanding | 15M | 18M | 15M | 3M | 3M | 1M |
| Metric | 2018 | 2019 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 25M | 1.0B | N/A | N/A | 0 | N/A | 0 |
| Gross Margin | N/A | 0.0% | N/A | N/A | N/A | N/A | N/A |
| R&D | 42M | N/A | 39M | 41M | 44M | 61M | 70M |
| SG&A | 16M | 19M | 22M | 18M | 11M | 23M | 28M |
| EBIT | -33M | -71M | -61M | -59M | -56M | -83M | -97M |
| Op. Margin | -130.5% | -7.1% | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -32M | -69M | -61M | -58M | -36M | -75M | -85M |
| Net Margin | -126.3% | -6.9% | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 1.4M | 0 | 91K | 0 |
| Returns on Capital | |||||||
| ROIC | -43.5% | -48.3% | -42.5% | -60.9% | -19.5% | -24.2% | N/M |
| ROE | -43.5% | N/A | -42.5% | -48.5% | -19.5% | -30.3% | -32.1% |
| ROA | -40.7% | -61.8% | -37.2% | -41.2% | -16.3% | -26.9% | -29.6% |
| Cash Flow | |||||||
| Op. Cash Flow | -32M | -15M | -48M | -46M | -51M | -71M | -77M |
| Free Cash Flow | -32M | -16M | -51M | -47M | -52M | -71M | -78M |
| Owner Earnings | -37M | -23M | -60M | -56M | -56M | -82M | -94M |
| CapEx | 49K | 879K | 3.3M | 1.1M | 321K | 808K | 1.2M |
| Maint. CapEx | 289K | 340K | 1.3M | 1.6M | 3.3M | 3.2M | 3.1M |
| Growth CapEx | 0 | 539K | 2.0M | 0 | 0 | 0 | 0 |
| D&A | 289K | 340K | 1.3M | 1.6M | 3.3M | 3.2M | 3.1M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | 0.0% | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 4.7M | 7.7M | 12M | 8.8M | 1.4M | 8.3M | 13M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -154M | -286M | -142M | -96M | -197M | -312M | -265M |
| Cash & Equiv. | 77M | 143M | 142M | 38M | 148M | 137M | 265M |
| Long-Term Debt | 6K | 146K | 67K | 233K | 65K | 26K | 7K |
| Debt/Equity | 0.00 | N/A | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | -8156.0 | -70959.0 | N/A | N/A | -4631.9 | -6883.8 | -6883.8 |
| Equity | 73M | N/A | 143M | 94M | 186M | 310M | 266M |
| Total Assets | 78M | 147M | 163M | 116M | 223M | 336M | 288M |
| Total Liabilities | 4.9M | N/A | 20M | 22M | 37M | 25M | 22M |
| Intangibles | N/A | 567K | 128K | 0 | N/A | N/A | N/A |
| Retained Earnings | -230M | -300M | -393M | -451M | -187M | -262M | -328M |
| Working Capital | 73M | 139M | 135M | 88M | 177M | 301M | 256M |
| Current Assets | 77M | 144M | 144M | 99M | 200M | 316M | 271M |
| Current Liabilities | 4.6M | 4.7M | 8.6M | 11M | 23M | 15M | 15M |
| Per Share Data | |||||||
| EPS | -26.80 | -51.40 | -22.00 | -20.80 | -2.43 | -4.28 | -4.10 |
| Owner EPS | -31.02 | -17.33 | -21.90 | -20.24 | -3.76 | -4.68 | -6.04 |
| Book Value | 61.66 | N/A | 51.79 | 34.09 | 12.46 | 17.68 | 17.14 |
| Cash Flow/Share | -26.79 | -11.39 | -17.24 | -16.48 | -3.44 | -4.02 | -5.30 |
| Dividends/Share | N/A | 0.00 | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.2M | 1.4M | 2.8M | 2.8M | 14.9M | 17.6M | 15.5M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -5.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 0.7 | N/A | 2.1 | 0.3 | 1.4 | 1.3 | 1.2 |
| Price/Sales | 7.6 | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -64.8% | N/A | -17.2% | -175.9% | -20.2% | -17.7% | -24.4% |
| Market Cap | 49M | 0 | 296M | 27M | 256M | 403M | 322M |
| Avg. Price | 161.64 | 0.00 | 189.56 | 29.55 | 14.23 | 36.24 | 20.76 |
| Year-End Price | 41.40 | 0.00 | 107.40 | 9.60 | 17.18 | 22.97 | 20.76 |
Neurogene Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Neurogene Inc. (NGNE) has a 5-year average return on invested capital (ROIC) of -39.1%. This is below average and may indicate limited pricing power.
Neurogene Inc. (NGNE) has a market capitalization of $322M. It is classified as a small-cap stock.
Neurogene Inc. (NGNE) does not currently pay a regular dividend.
Neurogene Inc. (NGNE) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Neurogene Inc. (NGNE) generated $-71 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Neurogene Inc. (NGNE) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Neurogene Inc. (NGNE) reported earnings per share (EPS) of $-4.28 in its most recent fiscal year.
Neurogene Inc. (NGNE) has a return on equity (ROE) of -30.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for Neurogene Inc. (NGNE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Neurogene Inc. (NGNE) has a book value per share of $17.68, based on its most recent annual SEC filing.